Ser443
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser443  -  EPB41L3 iso2 (human)

Site Information
KRYTMSRsLDGAsVN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486559

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:
breast cancer ( 4 ) , lung cancer ( 3 , 4 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 10 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 8 ) , A498 (renal) ( 9 ) , BT-20 (breast cell) ( 4 ) , BT-549 (breast cell) ( 4 ) , Calu 6 (pulmonary) ( 4 ) , Flp-In T-Rex-293 (epithelial) ( 5 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 5 ) , H2009 (pulmonary) ( 4 ) , H2077 (pulmonary) ( 4 ) , H2887 (pulmonary) ( 4 ) , H322 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HCC1359 (pulmonary) ( 4 ) , HCC1937 (breast cell) ( 4 ) , HCC2279 (pulmonary) ( 4 ) , HCC366 (pulmonary) ( 4 ) , HCC4006 (pulmonary) ( 4 ) , HCC827 (pulmonary) ( 4 ) , HOP62 (pulmonary) ( 4 ) , HUES-9 ('stem, embryonic') ( 7 ) , LCLC-103H (pulmonary) ( 4 ) , LOU-NH91 (squamous) ( 4 ) , lung ( 3 ) , MCF-7 (breast cell) ( 4 ) , MDA-MB-231 (breast cell) ( 4 ) , MDA-MB-468 (breast cell) ( 4 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H1568 (pulmonary) ( 4 ) , NCI-H157 (pulmonary) ( 4 ) , NCI-H1648 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 ) , NCI-H2172 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H520 (squamous) ( 4 ) , NCI-H647 (pulmonary) ( 4 ) , PC9 (pulmonary) ( 4 ) , U2OS (bone cell) [GR (human)] ( 11 ) , WM239A (epidermal) ( 2 )

References 

1

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

6

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

7

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

8

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

9

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

10

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

11

Lowery DM, et al. (2007) Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26, 2262-73
17446864   Curated Info